Home » Stocks » RVMD

Revolution Medicines, Inc. (RVMD)

Stock Price: $40.77 USD 0.75 (1.87%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $40.00 -0.77 (-1.89%) Jan 15, 7:27 PM
Market Cap 2.71B
Revenue (ttm) 46.32M
Net Income (ttm) -105.01M
Shares Out 64.89M
EPS (ttm) -21.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $40.77
Previous Close $40.02
Change ($) 0.75
Change (%) 1.87%
Day's Open 39.58
Day's Range 39.00 - 41.47
Day's Volume 825,228
52-Week Range 19.65 - 45.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...

Benzinga - 2 months ago

Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12....

GlobeNewsWire - 2 months ago

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

GlobeNewsWire - 2 months ago

Plenary Presentation at EORTC-NCI-AACR 3 2 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profile s for RMC-4630 Combined with Cobime...

GlobeNewsWire - 3 months ago

Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Study Findings Selected for Oral Presentation in ...

Zacks Investment Research - 3 months ago

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)

GlobeNewsWire - 4 months ago

REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to in...

GlobeNewsWire - 4 months ago

Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event Company’s Scientific Leadership to Deliver Presentations, Pa...

GlobeNewsWire - 5 months ago

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors

GlobeNewsWire - 6 months ago

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million

Zacks Investment Research - 6 months ago

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of ...

GlobeNewsWire - 6 months ago

Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus Newly Discovered Natural Product and Designed Analogues Bind to Human Pr...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit front...

GlobeNewsWire - 6 months ago

Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Ev...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit front...

GlobeNewsWire - 7 months ago

Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors

Kiplinger - 7 months ago

Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.

Other stocks mentioned: AMAT, BABA, BBIO, GH, LLNW, PLUG
GlobeNewsWire - 7 months ago

Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting

GlobeNewsWire - 8 months ago

Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million

GlobeNewsWire - 8 months ago

Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clin...

GlobeNewsWire - 9 months ago

Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630

GlobeNewsWire - 10 months ago

Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct ...

Seeking Alpha - 10 months ago

Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable

The Motley Fool - 10 months ago

Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.

GuruFocus - 10 months ago

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Other stocks mentioned: AMGN, MRTX
GlobeNewsWire - 10 months ago

REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusi...

24/7 Wall Street - 11 months ago

Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.

Market Watch - 11 months ago

Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a r...

About RVMD

Revolution Medicines, a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi f... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2020
CEO
Mark Goldsmith
Employees
117
Stock Exchange
NASDAQ
Ticker Symbol
RVMD
Full Company Profile

Financial Performance

In 2019, RVMD's revenue was $50.04 million, an increase of 148.16% compared to the previous year's $20.17 million. Losses were -$47.66 million, 14.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 46.25, which is an increase of 13.44% from the latest price.

Price Target
$46.25
(13.44% upside)
Analyst Consensus: Buy